Cancer Vaccines: Prevention, Protection During Cancer Care, and Emerging Treatment Approaches

The three conversations to have

If the table extends beyond your screen, swipe or scroll sideways to read every column.

A vaccine can be valuable without being an anticancer treatment. Preventing a serious infection can protect health and reduce disruption to cancer care. The right plan depends on the patient’s age, previous vaccinations, cancer, treatment and immune function—not simply the word cancer on the medical record.

Vaccines that help prevent cancer

HPV vaccination: protection before disease develops

Human papillomavirus, or HPV, is a group of viruses. Persistent infection with certain types can cause cervical and other anogenital cancers and some cancers of the throat. Vaccination prevents infection with the types covered by the vaccine and reduces the risk of associated cancers. It does not prevent every cancer or every HPV infection.

Protection is greatest before exposure, which is why vaccination programmes usually begin in adolescence. Boys as well as girls can benefit, according to the applicable programme and product. HPV is not solely a women’s health issue.

Vaccination after some previous exposure may still protect against types not yet acquired, but it does not clear an established infection or treat cervical cancer. Age, prior vaccination and local recommendations influence whether it is appropriate.

Vaccinated people who have a cervix still need recommended cervical screening. Screening and vaccination are complementary: one reduces risk from infection, while the other looks for relevant abnormalities or disease. A vaccination record is not a reason to ignore abnormal bleeding or other symptoms.

How many HPV doses are needed?

There is not one schedule for everyone worldwide. WHO permits reduced-dose schedules in certain age groups, while national programmes and product instructions may differ. Immunocompromised people, including some patients with cancer, may need additional doses and should not copy a healthy adolescent’s schedule.

Ask the vaccinating clinician to check the product, age at first dose, earlier doses, current cancer treatment and local policy. Avoid assuming that the newest internet headline about a single dose applies to every adult or to someone with significant immune suppression.

The useful decision is which complete schedule applies to you, not which brand is most prominently advertised. Keep the product name and dates in your medical record.

Hepatitis B vaccination and liver-cancer prevention

Chronic hepatitis B can cause liver disease and increase liver-cancer risk. Preventing hepatitis B infection through vaccination is therefore an important part of cancer prevention. It does not prevent all liver cancers or treat established hepatitis B.

Infant vaccination, including a timely birth dose under recommended programmes, is particularly important. Adults may also require vaccination depending on previous immunisation, infection status and risk.

For someone starting cancer treatment, the question is more complex than simply arranging another vaccine. The team may need to distinguish susceptibility to new infection from current or past hepatitis B that could reactivate. These require different preventive strategies.

Vaccination for people already diagnosed with cancer

Cancer and its treatment affect immunity in different ways. Intensive chemotherapy, blood cancers, B-cell-depleting treatment, transplantation and CAR-T may reduce vaccine responses substantially. Other treatments may have less effect.

Vaccination planning should be reviewed early, ideally before treatment where feasible. Bring previous records, including adult vaccines, not only childhood immunisations. The oncologist, primary-care clinician and vaccination service can share responsibility for the plan.

A vaccine’s safety and effectiveness are separate issues. A non-live vaccine may be safe to give during treatment but produce a weaker immune response. That can affect timing or the need for later doses without making vaccination pointless.

Which vaccines may be discussed?

If the table extends beyond your screen, swipe or scroll sideways to read every column.

This is a discussion guide, not a universal prescription. Products, schedules and availability differ between countries and may change. Ask for a written plan including what is due, when and who will administer it.

Should vaccination happen before cancer treatment?

When feasible, ASCO recommends addressing vaccination before treatment, ideally allowing approximately two to four weeks where appropriate. However, urgent cancer treatment should not be postponed simply to complete every vaccine. The team must balance timing, infection risk and the need to treat the cancer.

Some non-live vaccines can be given during or after chemotherapy, immunotherapy, radiotherapy, hormonal treatment or surgery, depending on the individual situation. Treatment cycle, blood counts, the specific vaccine and expected immune response may influence scheduling.

Do not skip a seasonal vaccine indefinitely because there is no perfect interval. Ask the team for the best available plan. Equally, do not arrive for vaccination without disclosing current treatment and immune-suppressing medicines.

Live and non-live vaccines need different thinking

Non-live vaccines cannot reproduce as an infection. They may use inactivated organisms, proteins, other components or genetic instructions that do not create the relevant live infection. Many can be used in immunocompromised patients, although protection may be reduced.

Live attenuated vaccines contain weakened organisms capable of limited replication. They may be unsafe during significant immune suppression. Examples include certain measles, varicella, travel and nasal influenza vaccines. Safety depends on the product and immune status; patients should not arrange them independently during active immunosuppressive treatment.

Do not assume that every vaccine against the same disease is identical. An injectable non-live flu vaccine is not the same product as a live nasal spray. A recombinant shingles vaccine is not interchangeable with a live shingles vaccine.

Tell the vaccination service about steroids, recent chemotherapy and blood-cancer treatment, not just the cancer diagnosis. The type, dose and duration of immune suppression can change the advice.

What changes after B-cell treatment, transplantation or CAR-T?

Treatments that reduce B cells can weaken antibody responses for a prolonged period. A usual adult schedule may need different timing or later reassessment. A recent vaccine does not always mean adequate protection in this setting.

Stem-cell transplantation and CAR-T can also require a planned revaccination programme. Which vaccines restart and when depends on immune recovery and the specialist pathway. Do not independently repeat the entire childhood schedule or use live vaccines because a particular number of months has passed.

Ask who owns the follow-up plan—the transplant or cellular-therapy team, oncologist or primary-care clinician—and ensure each has the vaccination record. Repeatedly being told to ask another service can leave necessary doses missed.

Hepatitis B reactivation: why vaccination alone is not enough

Some anticancer treatments can allow current or past hepatitis B infection to become active again. Vaccination prevents new infection; it does not reliably prevent reactivation in someone previously infected.

ASCO advises hepatitis B assessment before systemic anticancer treatment using tests that distinguish current infection, past exposure and immunity: HBsAg, anti-HBc and anti-HBs. Depending on the findings and regimen, antiviral medication and monitoring may be required. Cancer treatment should not be unnecessarily delayed while the care pathway is coordinated.

This distinction is particularly important before certain blood-cancer treatments. Do not interpret a past vaccine, a normal liver test or the absence of symptoms as proof that reactivation assessment is unnecessary.

Ask your oncologist: “Have my hepatitis B results been reviewed for the treatment I am receiving?” It is a different question from whether you are due a vaccine.

Protecting the household around the patient

Close contacts should generally keep age- and risk-appropriate vaccinations up to date. Protecting family members can reduce the chance of infections reaching a vulnerable patient. The healthy household’s schedule is not the same as the patient’s modified schedule.

Recommended routine vaccination of children should not be stopped simply because somebody at home has cancer. Particular live vaccines can require specific advice. Oral polio vaccine (OPV) should be avoided for household contacts of an immunocompromised person. Tell the vaccinating team about immune suppression at home before polio vaccination, and ask about the non-live, injected polio vaccine (IPV) and the appropriate schedule. If oral polio vaccine has already been given, contact the oncology team for advice on precautions. Other precautions still apply: a contact who develops a rash after varicella vaccination should avoid close contact with a susceptible immunocompromised person until it resolves; careful handwashing is important after changing a baby’s nappies following rotavirus vaccination. Tell the child’s vaccinator about significant immune suppression at home so relevant precautions can be explained.

Vaccination does not replace sensible infection precautions. Visitors who are acutely unwell should postpone close contact. Hand hygiene, appropriate ventilation, safe food and water, and masking when advised for particular risks remain useful.

The aim is sensible protection, not isolating the patient from family life unnecessarily. Ask which precautions fit the actual treatment and immune status.

What about fever after vaccination?

Soreness and a brief systemic reaction can occur after vaccination. In a patient receiving chemotherapy or with significant immune suppression, however, fever should not automatically be dismissed as a vaccine effect. Infection may require urgent treatment.

Follow the oncology unit’s instructions. A temperature of 37.5°C (99.5°F) or above during chemotherapy warrants immediate contact and prompt assessment; do not wait for it to remain high for hours. Severe illness needs emergency care, even without fever.

Tell the assessing team the vaccine, date, cancer treatment and last treatment date. Do not use fever-lowering medicine to justify waiting at home.

Cancer-treatment vaccines: a different kind of protection

Therapeutic vaccines aim to stimulate or direct an immune response against an existing cancer. Strategies may use tumour-associated antigens, immune cells or personalised information from tumour mutations.

A personalised neoantigen vaccine is designed around abnormal features identified in an individual tumour. Making one can involve tissue sampling, sequencing, design and manufacture. This is not an off-the-shelf injection that works against every cancer.

Trials are testing these approaches, often alongside checkpoint inhibitors. A vaccine may help generate a tumour-directed response, while a checkpoint inhibitor reduces signals restraining immune cells. A plausible combination still needs clinical evidence showing meaningful benefit.

Which established treatments should not be confused?

Sipuleucel-T is a cellular immune treatment authorised in the United States for a defined metastatic castration-resistant prostate-cancer population. That is not an indication for all prostate cancer or evidence of routine availability in every country.

BCG is used inside the bladder for selected non-muscle-invasive bladder cancers. In this context it is local immunotherapy; it is not the childhood tuberculosis vaccine given in the ordinary way and does not establish that a BCG injection treats other cancers.

Oncolytic-virus treatments, such as T-VEC in selected melanoma settings, are another distinct immune approach. They should not be presented as personalised neoantigen vaccines or as vaccines preventing melanoma in healthy people.

Naming these differences helps patients evaluate offers described loosely as cancer vaccination.

How should I assess a personalised-vaccine claim?

Ask the exact product, cancer, stage and study. Was benefit demonstrated in a randomised trial, an early uncontrolled study or only laboratory research? Was the result an immune response, tumour shrinkage, reduced recurrence or longer survival? These are different outcomes.

Clarify regulatory status in the country of treatment, relevant guideline support, trial registration, costs, manufacturing time and alternatives. A product sold commercially is not automatically established standard care. An exciting presentation does not justify stopping an effective treatment without a careful specialist discussion.

Personalised therapeutic vaccination is not a routine substitute for established cancer treatment across diseases. For many approaches, access remains through clinical trials. Where an approval or other pathway is claimed, it needs product- and country-specific verification rather than a broad statement that cancer vaccines have arrived.

Frequently asked questions

Vaccination in cancer care is not one conversation. It is about preventing certain cancers, protecting the person receiving treatment and assessing emerging therapies without confusing their purposes.